



Luxembourg, 2 December 2021

## **Scientific Committee on Consumer Safety (SCCS)**

### **Meeting of the Working Group on Cosmetic Ingredients in Cosmetic Products**

23-24 November 2021, Luxembourg

### **Minutes**

#### **1. Welcome and apologies, approval of the agenda and declaration of interests**

The Chair welcomed the participants, and in particular the new external expert Dr Nicolas Cabaton. The meeting was organised via AUDIO.

One apology was received for ½ day each day of meeting due to participation in external meeting on behalf of the SCCS.

The agenda was adopted without changes.

The minutes of the previous meeting held on 5-6 October have been agreed by the members of the WG and published on the website:

[https://ec.europa.eu/health/scientific\\_committees/consumer\\_safety/minutes\\_wg\\_meetings\\_en](https://ec.europa.eu/health/scientific_committees/consumer_safety/minutes_wg_meetings_en)

The Chair invited participants to declare any interest regarding matters on the agenda. None of the participants declared any interest conflicting with the matters on the agenda.

#### **2. List of points discussed**

##### **2.1 New mandates or information from DG GROW**

- No new mandate was received: [SCCS - Mandates | Public Health \(europa.eu\)](#)
- DG GROW informed about the following potential mandates:
  - a. Benzophenone-1
  - b. Benzophenone-4
  - c. Methylparaben
  - d. OMC
  - e. Salicylic Acid

- f. Triphenyl Phosphate
- g. Benzyl Salicylate

## 2.2 Draft Opinions discussed

- Genistein: the draft preliminary Opinion has been discussed and tasks have been allocated to members. It is planned to be finalised during the next December meeting.
- Daidzein: the draft preliminary Opinion has been discussed and tasks have been allocated to members. It is planned to be finalised during the next December meeting.
- Revision of the Vitamin A Opinion: the draft preliminary Opinion has been finalised and will go through written procedure for adoption before the next December meeting.
- Aluminium (aggregate exposure): the draft preliminary Opinion has been presented and tasks have been allocated to members. A new request for clarification to the Applicant is under preparation.
- 4-Methylbenzylidene camphor (4-MBC): the draft preliminary Opinion has been discussed and tasks have been allocated to members. It is planned to be finalised during the next December meeting.
- Scientific Advice on Triclocarban and Triclosan: the draft document has been presented and will be further discussed at the next December meeting.
- Scientific Advice on Homosalate: the draft document has been finalised and will be adopted by written procedure after the meeting.
- Arbutins: the draft preliminary Opinion has been discussed and tasks have been allocated to members. It will be further discussed at the next December meeting.

## 2.3 Comments on Opinions

- The final Opinion on fragrance Methylsalicylate was published: [Opinion of the Scientific Committee on Consumer Safety on Methyl salicylate \(methyl 2-hydroxybenzoate\) \(europa.eu\)](#)
- A corrigendum on Lawsonia inermis (Henna) - SCCS/1511/13 was published [sccs\\_o\\_140.pdf \(europa.eu\)](#)  
Corrigenda made in the Opinion: Page 19: Percutaneous absorption in vitro. DAp of 4.08 % to be used for MoS calculation. Page 22: NOAEL of 2 mg/kg bw/d will be used for the MoS. Page 37: Revision of the calculation of the Margin of Safety (MoS) from 210 to 156. Page 39: Discussion on dermal absorption: DAp revised from 5.3% to 4.08%.
- The preliminary Opinion on kojic acid has been published for comment until 14 January 2022: [SCCS - Opinions 2016 - 2021 | Public Health \(europa.eu\)](#)

- Prostaglandins and prostaglandin-analogues used in cosmetic products - SCCS/1635/21: the comments received have been presented during the WG and will be further discussed in the next December meeting, together with some expected additional information.
- Butylated Hydroxytoluene (BHT) - SCCS/1636/21: the comments received have been discussed and the SCCS prepared their response. The final Opinion (unchanged), together with the SCCS response document will be adopted by written procedure after the meeting.

### **3. Information from Chairman/Members/Commission**

- The SCCS chair reported on the internal meeting held with mandating DG GROW who is working on their impact assessment options to be developed for the revision of the Cosmetic Products Regulation in the framework of the new chemical strategy. The SCCS reiterated their wish not to move to an EU Agency, to keep their independence, their safety assessment driven by exposure and not hazard only, and their precious knowledge and experience acquired with regard to alternative methods to animal testing.
- The SCCS vice-chair represented the SCCS in the BfR symposium on NAMs on 15-17 November 2021 and in the European Partnership for Alternative Approaches to Animal Testing (EPAA) workshop meeting on NAMS on 23-24 November.
- Two SCCS members are planning to participate on behalf of the SCCS in the Joint Cosmetics Europe and EU-ToxRisk Virtual Workshop on 3 December 2021.
- The SCCS vice-chair informed about the annual safety training course from VUB in 2022: potential participants have to fill out the online registration form accessible via the course website [www.safetycourse.eu](http://www.safetycourse.eu)
- The Secretariat informed about the tentative date of the next ED annual Forum on 10-11 May 2022 as an update on the SCCS challenges might be presented.

### **4. Next meetings**

20-21 December 2021, 18-19 January 2022 and 8-9 February 2022

### **5. A.O.B.**

/

-----